Company news
Vicore Pharma Holding Ab (OMXSTO:VICO) news
Vicore Pharma Holding Ab news releases on 6ix. Latest, Sep 17, 2026: Vicore Pharma to Present in The Stifel 2026 Virtual Immunology and Inflammation Forum
Press releases & updates
Vicore Pharma to Present in The Stifel 2026 Virtual Immunology and Inflammation Forum
September 17, 2026
Vicore Pharma Appoints Rob Slack as Chief Scientific Officer
July 6, 2026
Vicore Pharma to Commence Trading in the United States on The Nasdaq Stock Market
July 1, 2026
Vicore Pharma Pursues US Dual Listing, Files Registration Statement with the SEC
May 22, 2026
Vicore Pharma Elects Peter Guenter to its Board of Directors
May 7, 2026
Announcement from the Annual General Meeting of Vicore Pharma Holding AB (publ)
May 6, 2026
Vicore Pharma Announces Presentations at the 2026 American Thoracic Society International Conference
April 29, 2026
Vicore Pharma Completes Enrollment in the Phase 2b ASPIRE Trial of Buloxibutid in Idiopathic Pulmonary Fibrosis
April 22, 2026
Notice Of Annual General Meeting In Vicore Pharma Holding AB (PUBL)
April 1, 2026
Vicore Publishes the Annual Report for 2025
March 26, 2026
Vicore Pharma to Present at Upcoming Investor Conferences
March 9, 2026
Vicore Pharma Elevates Leadership Team Ahead of Key Clinical and Corporate Milestones
March 5, 2026
Vicore Pharma Holding AB - Year-end report 2025
March 2, 2026
Year-End Report 2025
February 27, 2026
Vicore Pharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 18, 2026
Vicore Pharma to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 7, 2026
Vicore Pharma To Move To The Nasdaq Stockholm Mid Cap Segment
December 19, 2025
Vicore to Present at the Oppenheimer Movers in Rare Disease Summit
December 5, 2025
Increase in Number of Shares and Votes in Vicore Pharma
November 28, 2025
Vicore to Present at the DNB Carnegie Nordic Healthcare Conference
November 20, 2025
Vicore to Present at The Jefferies Global Healthcare Conference in London
November 17, 2025
Vicore Pharma announces successful execution of a directed share issue of approximately USD 48 million (approximately SEK 455 million)
November 12, 2025
Vicore to Present at Upcoming Investor Conferences
November 5, 2025
Interim Report July - September 2025
November 5, 2025
Vicore Announces The Nomination Committee For The 2026 Annual General Meeting
November 3, 2025
Buloxibutid Receives Orphan Drug Designation in Japan for the Treatment of Idiopathic Pulmonary Fibrosis
September 30, 2025
Vicore Announces Presentations at the European Respiratory Society Congress 2025
September 23, 2025
Vicore to Present at Pareto Securities' 16th Annual Healthcare Conference
September 15, 2025
Interim Report April - June 2025
August 22, 2025
Vicore to Present at the Jefferies Global Healthcare Conference
May 28, 2025
Vicore Presents New Data at the 2025 American Thoracic Society International Conference
May 22, 2025
Interim Report January – March 2025
May 6, 2025
Vicore to Present at the Nordea Equities Healthcare Seminar
May 2, 2025
Vicore Announces Presentations at the 2025 American Thoracic Society International Conference
April 23, 2025